Clinical Trial Update: Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing [Phase 4]

View source ↗

Summary

Phase 4 trial on intermittent rituximab dosing for maintaining remission in ANCA vasculitis; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 4 | Status: TERMINATED | Results posted: 2023-07-27